IPNews® – Amarin Corporation has been granted a patent for its elevated triglycerides treatment last week by the USPTO. 

AMR101, its best-in-class prescription treatment for patients at risk for cardiovascular disease, is currently undergoing FDA approval.  A decision by the FDA for approval of AMR101 is expected in July.  To continue reading, click: Amarin Cardiovascular Patent Issues